Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

28/04/2016 - 1 minute

I had the chance to talk with Tetsuyuki Maruyama, the CSO of the relatively new Dementia Discovery Fund – our final interview for #BioTrinity2016 in London.

dementia_discovery_fund_alzheimersThe high risk nature of doing trials for Dementia patients means in the past the market for this area of Neurodegenerative disease has been tough.

However, the need for improved therapeutics for Dementia and Alzheimer’s – and the increasing incidence of such diseases means researchers are experiencing a ‘bounce back’.

Tetsuyuki explains how the financial returns for Dementia is not what is spurring this new revival – but a collaborative effort to better the lives of sufferers. This is in part what has inspired the Dementia Discovery Fund to be founded in October, as a global investment fund managed by SV Life Sciences.

The DDF acts as an intermediary between charity, industry and the government by investing into discovery research targeting Dementia, with a fund which currently stands at €90M ($100M).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!